Gefitinib
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 62 (15) , 2237-2248
- https://doi.org/10.2165/00003495-200262150-00008
Abstract
▴ Gefitinib (ZD1839) is an orally active selective inhibitor of epidermal growth factor receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways implicated in the proliferation and survival of cancer cells. ▴ In human non-small cell lung cancer (NSCLC) cell lines and xenografts, gefitinib dose-dependently inhibited cellular proliferation and tumour growth, and potentiated the cytotoxic effects of chemotherapy and/or radiation. ▴ Gefitinib is orally bioavailable and is cleared via the cytochrome P450 3A4 pathway. In patients receiving gefitinib (50 to 700 mg/day) in phase I trials, steady-state plasma concentration was reached in 7 to 10 days. ▴ In patients with advanced NSCLC who had failed one or two prior chemotherapies, gefitinib 250 or 500mg once daily induced an objective response in ≈19% of patients in a double-blind trial (n = 210). ▴ In another double-blind trial including 216 patients with NSCLC who had failed two or more prior chemotherapies, gefitinib 250 or 500mg once daily induced an objective response in 11.8 and 8.8% of patients, respectively; ≈40% showed an improvement in disease-related symptoms. ▴ Gefitinib was generally well tolerated and the most common adverse events were mild skin rashes and diarrhoea.Keywords
This publication has 23 references indexed in Scilit:
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancerSeminars in Oncology, 2002
- Tyrosine kinase inhibitors—ZD1839 (Iressa)Current Opinion in Oncology, 2001
- Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839Seminars in Oncology, 2001
- Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.2001
- Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.2000
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.2000
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996